Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614714 · ClinicalTrials.gov registry record · Phase 2
Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants
A Phase 2 study, sponsored by University of California, Davis.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT04614714 is a Phase 2 study that has not yet begun recruiting, run by University of California, Davis. The registered enrollment target is 40 participants.
The verdict
NCT04614714, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Davis.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study aims to evaluate the feasibility and effects of nicotinamide riboside (NR) supplementation in lactating mothers of infants expected to be hospitalized in the neonatal intensive care unit (NICU) for at least four weeks.
Interventions
- OTHER Placebo
- OTHER Nicotinamide Riboside (NR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614714
The ClinicalTrials.gov registry entry for NCT04614714 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04614714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04614714 about?
NCT04614714 is a clinical study titled "Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants". This study aims to evaluate the feasibility and effects of nicotinamide riboside (NR) supplementation in lactating mothers of infants expected to be hospitalized in the neonatal intensive care unit (NICU) for at least four weeks.
What is the current status of trial NCT04614714?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-06-01. Estimated completion is 2026-06-30.
What interventions are being tested in trial NCT04614714?
The interventions under investigation include: Placebo (OTHER), Nicotinamide Riboside (NR) (OTHER).
Who is sponsoring clinical trial NCT04614714?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.